scPharmaceuticals Inc. (NASDAQ:SCPH) Shares Bought by Captrust Financial Advisors

Captrust Financial Advisors grew its holdings in scPharmaceuticals Inc. (NASDAQ:SCPH) by 32.2% in the 3rd quarter, Holdings Channel reports. The institutional investor owned 18,539 shares of the company’s stock after buying an additional 4,513 shares during the quarter. Captrust Financial Advisors’ holdings in scPharmaceuticals were worth $85,000 at the end of the most recent reporting period.

Other hedge funds have also modified their holdings of the company. Rubric Capital Management LP increased its stake in scPharmaceuticals by 35.5% in the 3rd quarter. Rubric Capital Management LP now owns 4,775,000 shares of the company’s stock valued at $21,774,000 after purchasing an additional 1,250,000 shares in the last quarter. AIGH Capital Management LLC increased its position in scPharmaceuticals by 3.4% during the second quarter. AIGH Capital Management LLC now owns 3,504,365 shares of the company’s stock worth $15,244,000 after buying an additional 115,206 shares in the last quarter. King Luther Capital Management Corp increased its position in scPharmaceuticals by 0.9% during the third quarter. King Luther Capital Management Corp now owns 2,225,790 shares of the company’s stock worth $10,150,000 after buying an additional 20,650 shares in the last quarter. Suvretta Capital Management LLC purchased a new position in scPharmaceuticals during the third quarter worth $9,343,000. Finally, Thrivent Financial for Lutherans grew its position in shares of scPharmaceuticals by 1.4% in the third quarter. Thrivent Financial for Lutherans now owns 1,048,938 shares of the company’s stock valued at $4,783,000 after purchasing an additional 14,866 shares during the period. 89.52% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities research analysts have recently commented on SCPH shares. HC Wainwright reaffirmed a “buy” rating and issued a $18.00 price objective on shares of scPharmaceuticals in a research report on Thursday, November 14th. Craig Hallum lowered their price objective on scPharmaceuticals from $16.00 to $12.00 and set a “buy” rating for the company in a research report on Thursday, November 14th.

scPharmaceuticals Price Performance

Shares of NASDAQ:SCPH opened at $3.20 on Tuesday. The company has a market cap of $160.13 million, a P/E ratio of -1.68 and a beta of 0.14. The company has a quick ratio of 6.89, a current ratio of 8.08 and a debt-to-equity ratio of 1.66. scPharmaceuticals Inc. has a 52 week low of $3.08 and a 52 week high of $6.71. The business has a fifty day simple moving average of $3.88 and a 200-day simple moving average of $4.36.

scPharmaceuticals Company Profile

scPharmaceuticals Inc, a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. Its lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX.